{
    "company_name": "PRESCIENT THERAPEUTICS LIMITED",
    "address": "Level 4, 100 Albert Road, SOUTH MELBOURNE, VIC, AUSTRALIA, 3205",
    "summary": "Bio-pharmaceutical research and development investment.",
    "details": "Bio-pharmaceutical research and development investment.",
    "website": "https://ptxtherapeutics.com/",
    "stock_code": "PTX",
    "links": "['https://ptxtherapeutics.com/', '', 'https://ptxtherapeutics.com/', 'https://ptxtherapeutics.com/home/', 'https://ptxtherapeutics.com/about-us/', 'https://ptxtherapeutics.com/technology/', 'https://ptxtherapeutics.com/technology/', 'https://ptxtherapeutics.com/pipeline/', 'https://prescienttherapeutics.investorportal.com.au/', 'https://prescienttherapeutics.investorportal.com.au/', 'https://prescienttherapeutics.investorportal.com.au/investor-briefing/', 'https://prescienttherapeutics.investorportal.com.au/share-price-and-annoucements/', 'https://prescienttherapeutics.investorportal.com.au/corporate-governance-and-directory/', '#', 'https://ptxtherapeutics.com/news-and-media/', '#', 'https://prescienttherapeutics.investorportal.com.au/prescient-therapeutics-shareholder-replay-8th-june-2023/', 'https://prescienttherapeutics.investorportal.com.au/prescient-therapeutics-investor-replay-ptx100/', 'https://prescienttherapeutics.investorportal.com.au/prescient-therapeutics-investor-replay-cellpryme-a/', 'https://prescienttherapeutics.investorportal.com.au/prescient-therapeutics-investor-replay-10-june/', 'https://ptxtherapeutics.com/contact-us/', 'https://ptxtherapeutics.com/', 'https://ptxtherapeutics.com/about-us/', 'https://ptxtherapeutics.com/technology/', 'https://prescienttherapeutics.investorportal.com.au/investor-briefing/', 'https://ptxtherapeutics.com/technology/', 'https://ptxtherapeutics.com/technology/', 'https://ptxtherapeutics.com/technology/', 'https://ptxtherapeutics.com/technology/', 'https://prescienttherapeutics.investorportal.com.au/investor-briefing/', 'https://ptxtherapeutics.com/news-and-media/#webcast-media', 'https://prescienttherapeutics.investorportal.com.au/', 'https://ptxtherapeutics.com/about-us/', 'https://ptxtherapeutics.com/about-us/', 'https://ptxtherapeutics.com/about-us/', 'https://ptxtherapeutics.com/pipeline/', 'https://ptxtherapeutics.com/pipeline/', 'https://ptxtherapeutics.com/pipeline/', 'https://prescienttherapeutics.investorportal.com.au/', 'https://prescienttherapeutics.investorportal.com.au/', 'https://prescienttherapeutics.investorportal.com.au/', '#', 'https://www.proactiveinvestors.com.au/companies/news/1044729/prescient-therapeutics-to-present-ptx-100-results-at-5th-world-congress-of-cutaneous-lymphomas-1044729.html', 'https://www.proactiveinvestors.com.au/companies/news/1044729/prescient-therapeutics-to-present-ptx-100-results-at-5th-world-congress-of-cutaneous-lymphomas-1044729.html', 'https://www.proactiveinvestors.com.au/companies/news/1044729/prescient-therapeutics-to-present-ptx-100-results-at-5th-world-congress-of-cutaneous-lymphomas-1044729.html', 'https://www.proactiveinvestors.com.au/companies/news/1044729/prescient-therapeutics-to-present-ptx-100-results-at-5th-world-congress-of-cutaneous-lymphomas-1044729.html', 'https://www.proactiveinvestors.com.au/companies/news/1042617/prescient-therapeutics-on-cusp-of-value-creation-says-pitt-street-research-1042617.html', 'https://www.proactiveinvestors.com.au/companies/news/1042617/prescient-therapeutics-on-cusp-of-value-creation-says-pitt-street-research-1042617.html', 'https://kalkinemedia.com/au/news/featured-news/prescient-therapeutics-asx-ptx-advances-ptx-100-to-pivotal-phase-2-study', 'https://kalkinemedia.com/au/news/featured-news/prescient-therapeutics-asx-ptx-advances-ptx-100-to-pivotal-phase-2-study', 'https://www.proactiveinvestors.com.au/companies/news/1037804/prescient-therapeutics-secures-speculative-buy-recommendation-from-bioshares', 'https://www.proactiveinvestors.com.au/companies/news/1037804/prescient-therapeutics-secures-speculative-buy-recommendation-from-bioshares', 'https://ptxtherapeutics.com/news-and-media/', 'https://ptxtherapeutics.com/', 'https://www.facebook.com/ptxtherapeutics/', 'https://www.linkedin.com/company/prescient-therapeutics/', 'https://twitter.com/PTX_AUS', 'tel://+61396927222', 'tel://+61390779233', '/cdn-cgi/l/email-protection#553431383c3b1525212d213d302734253020213c36267b363a38', 'https://ptxtherapeutics.com/about-us/', 'https://ptxtherapeutics.com/technology/', 'https://ptxtherapeutics.com/pipeline/', 'https://prescienttherapeutics.investorportal.com.au/', 'https://reachmarkets.com.au', 'https://reachmarkets.com.au', '#', '', 'https://reachmarkets.com.au/financial-services-guide/', 'https://reachmarkets.com.au/privacy-reach/', 'https://www.legislation.gov.au/Details/C2018C00424/', 'https://www.legislation.gov.au/Details/C2018C00424/Html/Volume_3#_Toc528568622', 'https://www.legislation.gov.au/Details/C2018C00424/Html/Volume_4#_Toc528570321']",
    "images": "https://www.facebook.com/tr, //ptxtherapeutics.com/wp-content/uploads/2018/03/Prescient.png, //ptxtherapeutics.com/wp-content/uploads/2018/03/Prescient.png, //ptxtherapeutics.com/wp-content/uploads/2018/03/Prescient.png, //ptxtherapeutics.com/wp-content/uploads/2018/03/Prescient.png, //ptxtherapeutics.com/wp-content/uploads/2018/03/Prescient.png, //ptxtherapeutics.com/wp-content/uploads/2018/03/Prescient.png, https://ptxtherapeutics.com/wp-content/uploads/2020/05/group-10-1.png, https://ptxtherapeutics.com/wp-content/uploads/2020/05/icon-4.png, https://ptxtherapeutics.com/wp-content/uploads/2020/05/icon-4.png, https://ptxtherapeutics.com/wp-content/uploads/2020/05/icon-4.png, https://ptxtherapeutics.com/wp-content/uploads/2018/03/our-science-bg.jpg, https://ptxtherapeutics.com/wp-content/uploads/2023/05/Frame-565.png, https://ptxtherapeutics.com/wp-content/uploads/2020/05/box-img-1.jpg, https://ptxtherapeutics.com/wp-content/uploads/2020/05/box-img-2.jpg, https://ptxtherapeutics.com/wp-content/uploads/2020/05/box-img-3.jpg, https://ptxtherapeutics.com/wp-content/uploads/2020/07/logo.png, https://ptxtherapeutics.com/wp-content/uploads/2024/04/vk.jpg, https://ptxtherapeutics.com/wp-content/uploads/2024/04/vk.jpg, https://ptxtherapeutics.com/wp-content/uploads/2024/03/imgs.jpeg, https://ptxtherapeutics.com/wp-content/uploads/2024/01/ptx_10jan_01_10_2024_07_40_46_005789-min.png, https://ptxtherapeutics.com/wp-content/uploads/2024/01/Prescient-Therapeutics-secures-speculative-buy-recommendation-from-Bioshares.jpg, /wp-content/uploads/2018/03/logo-footer.png, https://reachmarkets.com.au/wp-content/uploads/2019/01/ft_facebook.png, https://reachmarkets.com.au/wp-content/uploads/2019/01/ft_linkedin.png, https://reachmarkets.com.au/wp-content/uploads/2019/01/ft_twitter.png, /wp-content/uploads/2018/03/ic-logo-reach.svg",
    "company_logo_link": "https://ptxtherapeutics.com/wp-content/uploads/2020/07/logo.png"
}